Since MYC-driven cancers [38] and high MISS-54 scored patients (which include high MYC expressors; Additional file 2: Table S4) have low therapeutic success and poorer survival (Additional file 1: Fig. S8), PCLX-001 treatment could potentially offer therapeutic benefits for these often heavily treated patients, although this will require to be validated in clinical trials. The gene discussed is MYC; the disease is cancer.